Dexcom, Inc. (DXCM) has been a significant topic of discussion among investors, with both encouraging and concerning events. Dexcom's innovations were highlighted at the
EASD 2025, drawing attention to their upcoming CGM features. The firm has received buy ratings, including from
Goldman Sachs and
BofA Securities. The company's earnings for Q1 surpassed Wall Street's key metrics predictions and Dexcom was named a top growth stock. However, Dexcom also faced scrutiny over the safety of its
G7 device, which led to a share price decline. The new FDA competitor, leadership change, and EASD data further influenced Dexcom's valuation. Legal investigations into Dexcom and short-seller reports raising device safety concerns about the G7 led to a drop in stock price. Dexcom has announced a CEO succession plan and that their interim CEO will be taking a medical leave. Amidst these changes, they've experienced some stock volatility, with increases alongside Q1 revenue beats, buyback, and dips due to areas of concern. The company has also managed to maintain strong returns despite some setbacks. Dexcom's G7 product received FDA approval, and the company is set to launch its 15-day wearable glucose management system in the US.
Dexcom DXCM News Analytics from Sat, 15 Feb 2025 08:00:00 GMT to Fri, 03 Oct 2025 16:45:00 GMT -
Rating 5
- Innovation 7
- Rumor -2
